LONG BEACH, Calif., June 26, 2026
Anivive Lifesciences has achieved a landmark milestone after the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine granted full approval for Laverdia® (verdinexor tablets), the first FDA-approved oral, at-home treatment for canine lymphoma. The approval converts the product’s previous conditional approval into full regulatory authorization, providing veterinarians with a new treatment option for one of the most common and aggressive cancers affecting dogs. Beyond its clinical significance, Laverdia® also becomes the first FDA-approved veterinary medicine developed through Anivive’s proprietary AI-enabled drug development platform, validating the company’s innovative approach to artificial intelligence-driven drug repurposing, clinical trial recruitment, and regulatory development. The approval marks a major advancement for veterinary oncology while reinforcing the growing role of AI in accelerating the discovery and commercialization of new animal health therapies.
FDA Approval Brings First Oral At-Home Treatment for Canine Lymphoma
The FDA’s full approval of Laverdia® provides veterinarians and pet owners with a convenient oral therapy designed for at-home administration, offering greater flexibility in managing canine lymphoma, one of the most frequently diagnosed cancers in dogs. Laverdia® works as an XPO1 (Exportin-1) inhibitor, selectively blocking nuclear export proteins involved in cancer cell survival and tumor progression. Clinical evaluations demonstrated promising anti-cancer activity alongside a favorable safety and tolerability profile, supporting its transition from conditional approval, first granted in 2021, to full FDA approval. Following commercialization through Dechra Veterinary Products, veterinarians across the United States will gain nationwide access to the therapy, supported by educational resources, dosing guidance, and comprehensive clinical support programs designed to improve treatment adoption and patient care.
AI-Driven Drug Development Validated Through Regulatory Success
The approval represents an important technological achievement for Anivive Lifesciences, as Laverdia® becomes the first product to successfully complete the company’s AI-enabled drug development cycle. Using its proprietary AniviveSELECT platform, researchers identified verdinexor as a promising candidate for canine lymphoma by integrating insights from human oncology with veterinary disease biology. The company’s AniviveTRIAL platform then utilized artificial intelligence, intelligent patient matching, digital recruitment, and centralized enrollment technologies to identify and recruit dogs for the pivotal clinical study, contributing approximately 40% of total patient enrollment. This integrated development model significantly accelerated clinical trial execution while demonstrating how artificial intelligence can improve efficiency across veterinary pharmaceutical research, from drug repurposing to regulatory approval.
Advertisement
Global Expansion Strengthens Veterinary Oncology Innovation
Following U.S. approval, Anivive Lifesciences is advancing regulatory submissions for Laverdia® in Australia, Brazil, Canada, Europe, Japan, and the United Kingdom, supporting its long-term strategy to expand access to innovative veterinary cancer treatments worldwide. The company is also evaluating verdinexor for additional canine and feline cancers as well as potential veterinary antiviral applications, while continuing to expand its SearchLight DNA™ next-generation genomic sequencing platform for companion animal oncology.
With the global veterinary oncology market expected to grow substantially over the coming decade, demand continues to increase for advanced therapies capable of improving treatment outcomes and quality of life for companion animals diagnosed with cancer. The approval of Laverdia® not only introduces a groundbreaking oral treatment for canine lymphoma but also validates a new model of AI-powered veterinary drug discovery, positioning Anivive Lifesciences at the forefront of innovation in animal health. As veterinary medicine increasingly adopts precision technologies and artificial intelligence, Laverdia® represents an important milestone in delivering more accessible, affordable, and scientifically advanced cancer therapies for companion animals worldwide.
Source: Anivive Lifesciences press release
